Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
Does social media bring commercial benefits to GSK? That's not exactly the point, according to Quayle and Morgan. "Increasing sales is not one of our KPIs", says Morgan, "although building ...
GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...
“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.
chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...
The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of ...
Luke Miels, GSK’s chief commercial officer, said: “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical ...
Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback